Expansion Opportunity Notable international footprint with installations across 6 continents and plans for continued growth, supported by recent equity and venture debt financing. Target healthcare networks and hospital groups expanding their pathology and LIS capabilities in the UK, Europe, North America, and Australia.

LIS Procurement ULTRA Laboratory Information System is already deployed in over 80 laboratories and integrated with cellular pathology at NUH, signaling strong product-market fit. Sales conversations can focus on expanding ULTRA reach within NHS trusts, private labs, and international reference labs seeking robust LIS for pathology operations.

Financing Momentum Recent £4 million venture debt and over £3 million equity investments indicate investor confidence and liquidity to support commercial expansion, product development, and international sales efforts. Leverage these funds to accelerate go-to-market, partnerships, and larger controlled deployments.

Talent Growth Significant headcount increase and new hires in 2026 reflect scaling capabilities, R&D and customer support capacity. This supports larger deployments, faster implementation cycles, and enhanced post-implementation service levels for customers.

Strategic Partnerships Active collaboration with universities and healthcare institutions (e.g., NUH integration) demonstrates credibility and potential for co-development, pilots, and reference sites. Use these relationships to propose joint pilots, data interoperability projects, and CPD-aligned demonstrations for pathology networks.